BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

548 related articles for article (PubMed ID: 31563963)

  • 21. Radiomics MRI Phenotyping with Machine Learning to Predict the Grade of Lower-Grade Gliomas: A Study Focused on Nonenhancing Tumors.
    Park YW; Choi YS; Ahn SS; Chang JH; Kim SH; Lee SK
    Korean J Radiol; 2019 Sep; 20(9):1381-1389. PubMed ID: 31464116
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location.
    Karremann M; Gielen GH; Hoffmann M; Wiese M; Colditz N; Warmuth-Metz M; Bison B; Claviez A; van Vuurden DG; von Bueren AO; Gessi M; Kühnle I; Hans VH; Benesch M; Sturm D; Kortmann RD; Waha A; Pietsch T; Kramm CM
    Neuro Oncol; 2018 Jan; 20(1):123-131. PubMed ID: 29016894
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diffuse midline glioma with H3 K27M-mutation in an 83-year-old woman.
    Low JT; Wang SH; B Peters K
    CNS Oncol; 2021 Jun; 10(2):CNS71. PubMed ID: 33908265
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.
    Chi AS; Tarapore RS; Hall MD; Shonka N; Gardner S; Umemura Y; Sumrall A; Khatib Z; Mueller S; Kline C; Zaky W; Khatua S; Weathers SP; Odia Y; Niazi TN; Daghistani D; Cherrick I; Korones D; Karajannis MA; Kong XT; Minturn J; Waanders A; Arillaga-Romany I; Batchelor T; Wen PY; Merdinger K; Schalop L; Stogniew M; Allen JE; Oster W; Mehta MP
    J Neurooncol; 2019 Oct; 145(1):97-105. PubMed ID: 31456142
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Co-occurrence of histone H3 K27M and BRAF V600E mutations in paediatric midline grade I ganglioglioma.
    Pagès M; Beccaria K; Boddaert N; Saffroy R; Besnard A; Castel D; Fina F; Barets D; Barret E; Lacroix L; Bielle F; Andreiuolo F; Tauziède-Espariat A; Figarella-Branger D; Puget S; Grill J; Chrétien F; Varlet P
    Brain Pathol; 2018 Jan; 28(1):103-111. PubMed ID: 27984673
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Usefulness of magnetic resonance imaging characteristics in discriminating H3 K27M-mutant gliomas from wildtype gliomas in spinal cord.
    Zhao B; Yao J; Wang J; Li J; Shi W; Zhang C; Zhao X; Qiao J; Ma Y; Xu Y; Zheng Z
    Neurol Sci; 2024 Jun; 45(6):2845-2851. PubMed ID: 38228940
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiomics-Based Machine Learning to Predict Recurrence in Glioma Patients Using Magnetic Resonance Imaging.
    Hu G; Hu X; Yang K; Yu Y; Jiang Z; Liu Y; Liu D; Hu X; Xiao H; Zou Y; You Y; Liu H; Chen J
    J Comput Assist Tomogr; 2023 Jan-Feb 01; 47(1):129-135. PubMed ID: 36194851
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MRI-based radiomics signature and clinical factor for predicting H3K27M mutation in pediatric high-grade gliomas located in the midline of the brain.
    Wu C; Zheng H; Li J; Zhang Y; Duan S; Li Y; Wang D
    Eur Radiol; 2022 Mar; 32(3):1813-1822. PubMed ID: 34655310
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radiomics-based machine learning methods for isocitrate dehydrogenase genotype prediction of diffuse gliomas.
    Wu S; Meng J; Yu Q; Li P; Fu S
    J Cancer Res Clin Oncol; 2019 Mar; 145(3):543-550. PubMed ID: 30719536
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tectal Low-Grade Glioma with H3 K27M Mutation.
    Sumi K; Shijo K; Igarashi T; Yamamuro S; Sasano M; Oshima H; Ishige T; Honma T; Yagasaki H; Yoshino A
    World Neurosurg; 2020 Sep; 141():91-100. PubMed ID: 32505657
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-Invasive Prediction of Survival Time of Midline Glioma Patients Using Machine Learning on Multiparametric MRI Radiomics Features.
    Deng DB; Liao YT; Zhou JF; Cheng LN; He P; Wu SN; Wang WS; Zhou Q
    Front Neurol; 2022; 13():866274. PubMed ID: 35585843
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Machine learning and radiomic phenotyping of lower grade gliomas: improving survival prediction.
    Choi YS; Ahn SS; Chang JH; Kang SG; Kim EH; Kim SH; Jain R; Lee SK
    Eur Radiol; 2020 Jul; 30(7):3834-3842. PubMed ID: 32162004
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diffuse Midline Gliomas with Histone H3-K27M Mutation: A Series of 47 Cases Assessing the Spectrum of Morphologic Variation and Associated Genetic Alterations.
    Solomon DA; Wood MD; Tihan T; Bollen AW; Gupta N; Phillips JJ; Perry A
    Brain Pathol; 2016 Sep; 26(5):569-80. PubMed ID: 26517431
    [TBL] [Abstract][Full Text] [Related]  

  • 34. H3F3A mutant allele specific imbalance in an aggressive subtype of diffuse midline glioma, H3 K27M-mutant.
    Maeda S; Ohka F; Okuno Y; Aoki K; Motomura K; Takeuchi K; Kusakari H; Yanagisawa N; Sato S; Yamaguchi J; Tanahashi K; Hirano M; Kato A; Shimizu H; Kitano Y; Yamazaki S; Yamashita S; Takeshima H; Shinjo K; Kondo Y; Wakabayashi T; Natsume A
    Acta Neuropathol Commun; 2020 Feb; 8(1):8. PubMed ID: 32019606
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of Radiomics Analyses Based on Different Magnetic Resonance Imaging Sequences in Grading and Molecular Genomic Typing of Glioma.
    Huang WY; Wen LH; Wu G; Hu MZ; Zhang CC; Chen F; Zhao JN
    J Comput Assist Tomogr; 2021 Jan-Feb 01; 45(1):110-120. PubMed ID: 33475317
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort.
    Odia Y; Hall MD; Cloughesy TF; Wen PY; Arrillaga-Romany I; Daghistani D; Mehta MP; Tarapore RS; Ramage SC; Allen JE
    Neuro Oncol; 2024 May; 26(Supplement_2):S165-S172. PubMed ID: 38386699
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An adult case of diffuse midline glioma with H3 K27M mutation.
    Tu JH; Piao YS; Lu DH; Wang LM; Liu L; Bai DY; Han HW; Lin YK; Zhong S
    Neuropathology; 2020 Dec; 40(6):627-631. PubMed ID: 32954563
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Application of Automated Machine Learning Based on Radiomics Features of T2WI and RS-EPI DWI to Predict Preoperative T Staging of Rectal Cancer].
    Wen DG; Hu SX; Li ZL; Deng XB; Tian C; Li X; Wang XR; Leng Q; Xia CC
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2021 Jul; 52(4):698-705. PubMed ID: 34323052
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Slow-Growing Thalamic Glioma with Histone H3 Lysine 27-to-Methionine Mutation: 3-Year Follow-Up Before Surgical Intervention.
    Chanchotisatien A; Pan J; Du Z; Qiu T; Yu J; Chu S
    World Neurosurg; 2019 Jul; 127():266-268. PubMed ID: 30981797
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fusion Radiomics Features from Conventional MRI Predict MGMT Promoter Methylation Status in Lower Grade Gliomas.
    Jiang C; Kong Z; Liu S; Feng S; Zhang Y; Zhu R; Chen W; Wang Y; Lyu Y; You H; Zhao D; Wang R; Wang Y; Ma W; Feng F
    Eur J Radiol; 2019 Dec; 121():108714. PubMed ID: 31704598
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.